Derailed Intraneuronal Signalling Drives Pathogenesis in Sporadic and Familial Alzheimer's Disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Van Dooren, Tom ^a   Princen, Katrien ^a   De Witte, Koen ^a   Griffioen, Gerard ^a  

^a ReMYND ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE RECEPTOR; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CRIME; ENDOCYTOSIS; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR MECHANICS; NERVE CELL DEGENERATION; NERVE DEGENERATION; POSITIVE FEEDBACK; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION;

ALZHEIMER DISEASE; ANIMALS; ENDOCYTOSIS; HUMANS; NERVE DEGENERATION; NEURONS; PHOSPHORYLATION; RISK FACTORS; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84935892215     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/167024     Document Type: Article

References (207)

1. D. J. Selkoe, "Alzheimers disease is a synaptic failure, " Science, vol. 298, no. 5594, pp. 789-791, 2002.
2. D. J. Selkoe, "Alzheimers disease, " Cold Spring Harbor Perspectives in Biology, vol. 3, no. 7, pp. 1-16, 2011.
3. R. J. OBrien and P. C. Wong, "Amyloid precursor protein processing and alzheimers disease, "Annual ReviewofNeuroscience, vol. 34, pp. 185-204, 2011.
4. M. Morris, S. Maeda, K. Vossel, and L. Mucke, "The many faces of tau, " Neuron, vol. 70, no. 3, pp. 410-426, 2011.
5. W. Noble, D. P. Hanger, C. C. Miller, and S. Lovestone, "The importance of tau phosphorylation for neurodegenerative diseases, " Frontiers in Neurology, vol. 4, article 83, 2013.
6. L. Martin, X. Latypova, C. M. Wilsonet al., "Tauproteinkinases: involvement in Alzheimers disease, " Ageing Research Reviews, vol. 12, no. 1, pp. 289-309, 2013.
7. C. Liu, T. Kanekiyo, H. Xu, and G. Bu, "Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy, " Nature Reviews Neurology, vol. 9, no. 2, pp. 106-118, 2013.
8. R. Mayeux and Y. Stern, "Epidemiology of Alzheimer disease, " Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 8, 2012.
9. J. Brouillette, R. Caillierez, N. Zommer et al., "Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model, " Journal of Neuroscience, vol. 32, no. 23, pp. 7852-7861, 2012.
10. G. Forloni and C. Balducci, " β-amyloid oligomers and prion protein: fatal attraction?" Prion, vol. 5, no. 1, pp. 10-15, 2011.
11. A. Itkin, V. Dupres, Y. F. Dufrene, B. Bechinger, J. Ruysschaert, and V. Raussens, "Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimers disease, " PLoS ONE, vol. 6, no. 3, Article ID e18250, 2011.
12. A. L. Lublin and S. Gandy, "Amyloid-β oligomers: possible roles as key neurotoxins in Alzheimers disease, "Mount Sinai Journal of Medicine, vol. 77, no. 1, pp. 43-49, 2010.
13. A. J. Minano-Molina, J. Espana, E. Martin et al., "Soluble oligomers of amyloid-β peptide disrupt membrane trafficking of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction, "The Journal of Biological Chemistry, vol. 286, no. 31, pp. 27311-27321, 2011.
14. K. Ono and M. Yamada, "Low-n oligomers as therapeutic targets of Alzheimers disease, " Journal of Neurochemistry, vol. 117, no. 1, pp. 19-28, 2011.
15. T. Umeda, T. Tomiyama, N. Sakama et al., "Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo, " Journal of Neuroscience Research, vol. 89, no. 7, pp. 1031-1042, 2011.
16. Y. Jiang, K. A. Mullaney, C. M. Peterhoff et al., "Alzheimersrelated endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1630-1635, 2010.
17. K. Ghosal, D. L. Vogt, M. Liang, Y. Shen, B. T. Lamb, and S. W. Pimplikar, "Alzheimers disease-like pathological features in transgenic mice expressing the APP intracellular domain, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 43, pp. 18367-18372, 2009.
18. G. Schettini, S. Govoni, M. Racchi, and G. Rodriguez, "Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role-relevance for Alzheimer pathology, " Journal of Neurochemistry, vol. 115, no. 6, pp. 1299-1308, 2010.
19. A. N. Patel and J. H. Jhamandas, "Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain, " Expert Reviews inMolecularMedicine, vol. 14, article e2, 19 pages, 2012.
20. S. Hong, B. L. Ostaszewski, T. Yang et al., "SolubleAβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes, " Neuron, vol. 82, no. 2, pp. 308-319, 2014.
21. R. W. Ledeen and G. Wu, "Ganglioside function in calcium homeostasis and signaling, " Neurochemical Research, vol. 27, no. 7-8, pp. 637-647, 2002.
22. J. C. Augustinack, A. Schneider, E. Mandelkow, and B. T. Hyman, "Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimers disease, " Acta Neuropathologica, vol. 103, no. 1, pp. 26-35, 2002.
23. W. H. Stoothoff and G. V. W. Johnson, "Tau phosphorylation: physiological and pathological consequences, " Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1739, no. 2, pp. 280-297, 2005.
24. A. Thathiah and B. De Strooper, "The role of G protein-coupled receptors in the pathology of Alzheimers disease, " Nature Reviews Neuroscience, vol. 12, no. 2, pp. 73-87, 2011.
25. A. Thathiah, K. Spittaels, M. Hoffmann et al., "The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons, " Science, vol. 323, no. 5916, pp. 946-951, 2009.
26. G. Mairet-Coello and F. Polleux, "Involvement of stressresponse kinase pathways in Alzheimers disease progression, " Current Opinion in Neurobiology, vol. 27, pp. 110-117, 2014.
27. S. O. Yoon, D. J. Park, J. C. Ryu et al., "JNK3 perpetuates metabolic stress induced by Aβ peptides, " Neuron, vol. 75, no. 5, pp. 824-837, 2012.
28. Y. Ruiz-Leon and A. Pascual, "Regulation of β-amyloid precursor protein expression by brain-derived neurotrophic factor involves activation of both the Ras and phosphatidylinositide 3-kinase signalling pathways, " Journal of Neurochemistry, vol. 88, no. 4, pp. 1010-1018, 2004.
29. N. Mitsuda, N. Ohkubo, M. Tamatani et al., "Activated cAMPresponse element-binding protein regulates neuronal expression of presenilin-1, " Journal of Biological Chemistry, vol. 276, no. 13, pp. 9688-9698, 2001.
30. S. Mizuno, R. Iijima, S. Ogishima et al., "AlzPathway: a comprehensive map of signaling pathways of Alzheimers disease, " BMC Systems Biology, vol. 6, article 52, 2012.
31. A. Sorkin and M. Von Zastrow, "Endocytosis and signalling: intertwining molecular networks, " Nature Reviews Molecular Cell Biology, vol. 10, no. 9, pp. 609-622, 2009.
32. J. E. Murphy, B. E. Padilla, B. Hasdemir, G. S. Cottrell, and N. W. Bunnett, "Endosomes: a legitimate platformfor the signaling train, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 42, pp. 17615-17622, 2009.
33. R. Dobrowolski and E. M. de Robertis, "Endocytic control of growth factor signalling: multivesicular bodies as signalling organelles, " Nature Reviews Molecular Cell Biology, vol. 13, no. 1, pp. 53-60, 2012.
34. L. S. Zweifel, R. Kuruvilla, and D. D. Ginty, "Functions and mechanisms of retrograde neurotrophin signalling, " Nature Reviews Neuroscience, vol. 6, no. 8, pp. 615-625, 2005.
35. M. Ascano, D. Bodmer, and R. Kuruvilla, "Endocytic trafficking of neurotrophins in neural development, " Trends in Cell Biology, vol. 22, no. 5, pp. 266-273, 2012.
36. H. W. Platta and H. Stenmark, "Endocytosis and signaling, " Current Opinion in Cell Biology, vol. 23, no. 4, pp. 393-403, 2011.
37. A. Kikuchi, H. Yamamoto, and A. Sato, "Selective activation mechanisms ofWnt signaling pathways, " Trends in Cell Biology, vol. 19, no. 3, pp. 119-129, 2009.
38. G. Di Paolo and P. De Camilli, "Phosphoinositides in cell regulation and membrane dynamics, " Nature, vol. 443, no. 7112, pp. 651-657, 2006.
39. R. A. Nixon, "Endosome function and dysfunction in Alzheimers disease and other neurodegenerative diseases, " Neurobiology of Aging, vol. 26, no. 3, pp. 373-382, 2005.
40. A. M. Cataldo, C. M. Peterhoff, J. C. Troncoso, T. Gomez-Isla, B. T. Hyman, and R. A. Nixon, "Endocytic pathway abnormalities precede amyloid β deposition in sporadic alzheimers disease and down syndrome: differential effects of APOE genotype and presenilin mutations, " The American Journal of Pathology, vol. 157, no. 1, pp. 277-286, 2000.
41. S. D. Ginsberg, M. J. Alldred, S. E. Counts et al., "Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimers disease progression, " Biological Psychiatry, vol. 68, no. 10, pp. 885-893, 2010.
42. R. G. Nagele, M. R. DAndrea, W. J. Anderson, and H.-Y. Wang, "Intracellular accumulation of β-amyloid1-42 in neurons is facilitated by the α7 nicotinic acetylcholine receptor in Alzheimers disease, " Neuroscience, vol. 110, no. 2, pp. 199-211, 2002.
43. Y. Goto, T. Niidome, A. Akaike, T. Kihara, and H. Sugimoto, "Amyloid β-peptide preconditioning reduces glutamateinduced neurotoxicity by promoting endocytosis of NMDA receptor, " Biochemical and Biophysical Research Communications, vol. 351, no. 1, pp. 259-265, 2006.
44. D. Wang, E. Y. Yuen, Y. Zhou, Z. Yan, andY. K. Xiang, "Amyloid β peptide-(1 -42) induces internalization and degradation of β2 adrenergic receptors in prefrontal cortical neurons, " Journal of Biological Chemistry, vol. 286, no. 36, pp. 31852-31863, 2011.
45. A. Bulbarelli, E. Lonati, E. Cazzaniga et al., "TrkA pathway activation induced by amyloid-beta (Abeta), " Molecular and Cellular Neuroscience, vol. 40, no. 3, pp. 365-373, 2009.
46. O. Stohr, K. Schilbach, L. Moll et al., "Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease, " Age, vol. 35, no. 1, pp. 83-101, 2013.
47. C. ONeill, "PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimers disease, " Experimental Gerontology, vol. 48, no. 7, pp. 647-653, 2013.
48. R. J. Griffin, A. Moloney, M. Kelliher et al., "Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimers disease pathology, " Journal of Neurochemistry, vol. 93, no. 1, pp. 105-117, 2005.
49. V. Cavalli, F. Vilbois, M. Corti et al., "The stress-induced MAP kinase p38 regulates endocytic trafficking via the GDI:Rab5 complex, " Molecular Cell, vol. 7, no. 2, pp. 421-432, 2001.
50. F. Zhou, K. Gong, B. Song et al., "The APP intracellular domain (AICD) inhibits Wnt signalling and promotes neurite outgrowth, " Biochimica et Biophysica Acta, vol. 1823, no. 8, pp. 1233-1241, 2012.
51. J. R. Cirrito, J. Kang, J. Lee et al., "Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo, " Neuron, vol. 58, no. 1, pp. 42-51, 2008.
52. C. Yu, E. Nwabuisi-Heath, K. Laxton, and M. J. Ladu, "Endocytic pathways mediating oligomeric Aβ42 neurotoxicity, " Molecular Neurodegeneration, vol. 5, no. 1, article 19, 2010.
53. S. A. Small and S. Gandy, "Sorting through the cell biology of Alzheimers disease: intracellular pathways to pathogenesis, " Neuron, vol. 52, no. 1, pp. 15-31, 2006.
54. J. Wu, R. S. Petralia, H. Kurushima et al., "Arc/Arg3. 1 Regulates an endosomal pathway essential for activity-dependent β-amyloid generation, " Cell, vol. 147, no. 3, pp. 615-628, 2011.
55. V. Udayar, V. Buggia-Prevot, R. L. Guerreiro et al., "A Paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of beta-amyloid production, " Cell Reports, vol. 5, no. 6, pp. 1536-1551, 2013.
56. U. Das, D. A. Scott, A. Ganguly, E. H. Koo, Y. Tang, and S. Roy, "Activity-induced convergence of app and BACE-1 in acidic microdomains via an endocytosis-dependent pathway, " Neuron, vol. 79, no. 3, pp. 447-460, 2013.
57. R. M. Carey, B. A. Balcz, I. Lopez-Coviella, and B. E. Slack, "Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein, " BMC Cell Biology, vol. 6, article 30, 2005.
58. V. Buggia-Prevot, C. G. Fernandez, V. Udayar et al., "A function for EHD family proteins in unidirectional retrograde dendritic transport of BACE1 and Alzheimers disease Abeta production, " Cell Reports, vol. 5, no. 6, pp. 1552-1563, 2013.
59. R. Sannerud, I. Declerck, A. Peric et al., "ADP ribosylation factor (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. E559-E568, 2011.
60. P. G. Ulery, J. Beers, I. Mikhailenko et al., "Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimers disease, " Journal of Biological Chemistry, vol. 275, no. 10, pp. 7410-7415, 2000.
61. M. Nizzari, S. Thellung, A. Corsaro et al., "Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling, " Journal of Toxicology, vol. 2012, Article ID187297, 13 pages, 2012.
62. K. S. Vetrivel, Y. Zhang, H. Xu, andG. Thinakaran, "Pathological and physiological functions of presenilins, "Molecular Neurodegeneration, vol. 1, no. 1, article 4, 2006.
63. C. Haass and B. de Strooper, "The presenilins in Alzheimers disease-proteolysis holds the key, " Science, vol. 286, no. 5441, pp. 916-919, 1999.
64. M. Muller, C. Cardenas, L. Mei, K. Cheung, and J. K. Foskett, "Constitutive cAMP response element binding protein (CREB) activation by Alzheimers disease presenilin-driven inositol trisphosphate receptor (InsP3R) Ca2+ signaling, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 32, pp. 13293-13298, 2011.
65. N. Dehvari, O. Isacsson, B. Winblad, A. Cedazo-Minguez, and R. F. Cowburn, "Presenilin regulates extracellular regulated kinase (Erk) activity by a protein kinase C alpha dependent mechanism, " Neuroscience Letters, vol. 436, no. 1, pp. 77-80, 2008.
66. L. Baki, J. Shioi, P. Wen et al., "PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations, " The EMBO Journal, vol. 23, no. 13, pp. 2586-2596, 2004.
67. M. Nizzari, V. Venezia, E. Repetto et al., "Amyloid precursor protein and presenilin1 interact with the adaptor GRB2 and modulate ERK1, 2 signaling, " The Journal of Biological Chemistry, vol. 282, no. 18, pp. 13833-13844, 2007.
68. Y. Chen, X. Huang, Y. Zhang et al., "Alzheimers β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid, " The Journal of Neuroscience, vol. 32, no. 33, pp. 11390-11395, 2012.
69. T. Jonsson, J. K. Atwal, S. Steinberg et al., "A mutation in APP protects against Alzheimers disease and age-related cognitive decline, " Nature, vol. 487, no. 7409, pp. 96-99, 2012.
70. M. Hutton, C. L. Lendon, P. Rizzu et al., "Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17, " Nature, vol. 393, no. 6686, pp. 702-705, 1998.
71. M. Goedert, R. A. Crowther, and M. G. Spillantini, "Tau mutations cause frontotemporal dementias, " Neuron, vol. 21, no. 5, pp. 955-958, 1998.
72. M. G. Spillantini, J. R. Murrell, M. Goedert, M. R. Farlow, A. Klug, and B. Ghetti, "Mutation in the tau gene in familial multiple system tauopathy with presenile dementia, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7737-7741, 1998.
73. E. D. Roberson, K. Scearce-Levie, J. J. Palop et al., "Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimers disease mouse model, " Science, vol. 316, no. 5825, pp. 750-754, 2007.
74. K. Santacruz, J. Lewis, T. Spires et al., "Tau suppression in a neurodegenerative mouse model improves memory function, " Science, vol. 309, no. 5733, pp. 476-481, 2005.
75. L. M. Ittner, Y. D. Ke, F. Delerue et al., "Dendritic function of tau mediates amyloid-β toxicity in Alzheimer's disease mouse models, " Cell, vol. 142, no. 3, pp. 387-397, 2010.
76. S. Mondragon-Rodriguez, E. Trillaud-Doppia, A. Dudilot et al., "Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation, " Journal of Biological Chemistry, vol. 287, no. 38, pp. 32040-32053, 2012.
77. J. W. Um, H. B. Nygaard, J. K. Heiss et al., "Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons, " Nature Neuroscience, vol. 15, no. 9, pp. 1227-1235, 2012.
78. G. Amadoro, M. T. Ciotti, M. Costanzi, V. Cestari, P. Calissano, and N. Canu, "NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 8, pp. 2892-2897, 2006.
79. J. W. Um, A. C. Kaufman, M. Kostylev et al., "Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein, " Neuron, vol. 79, no. 5, pp. 887-902, 2013.
80. C. J. Leugers and G. Lee, "Tau potentiates nerve growth factorinducedmitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding, " Journal of Biological Chemistry, vol. 285, no. 25, pp. 19125-19134, 2010.
81. V. M. Sharma, J. M. Litersky, K. Bhaskar, and G. Lee, "Tau impacts on growth-factor-stimulated actin remodeling," Journal of Cell Science, vol. 120, no. 5, pp. 748757, 2007.
82. G. Lee, S. Todd Newman, D. L. Gard, H. Band, and G. Panchamoorthy, "Tau interacts with src-family non-receptor tyrosine kinases, " Journal of Cell Science, vol. 111, no. 21, pp. 3167-3177, 1998.
83. S. C. Hwang, D. Jhon, Y. S. Bae, J. H. Kim, and S. G. Rhee, "Activation of phospholipase C-γ by the concerted action of tau proteins and arachidonic acid, " The Journal of Biological Chemistry, vol. 271, no. 31, pp. 18342-18349, 1996.
84. C. Yoshizaki, M. Tsukane, and T. Yamauchi, "Overexpression of tau leads to the stimulation of neurite outgrowth, the activation of caspase 3 activity, and accumulation and phosphorylation of tau in neuroblastoma cells on cAMP treatment, " Neuroscience Research, vol. 49, no. 4, pp. 363-371, 2004.
85. J. Biernat, Y. Wu, T. Timm et al., "Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity, " Molecular Biology of the Cell, vol. 13, no. 11, pp. 4013-4028, 2002.
86. M. E. Seward, E. Swanson, A. Norambuena et al., "Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in alzheimers disease, " Journal of Cell Science, vol. 126, no. 5, pp. 1278-1286, 2013.
87. F. J. Hoerndli, S. Pelech, A. Papassotiropoulos, and J. Gotz, "Aβ treatment and P301L tau expression in an Alzheimers disease tissue culture model act synergistically to promote aberrant cell cycle re-entry, " European Journal of Neuroscience, vol. 26, no. 1, pp. 60-72, 2007.
88. K. Bhaskar, S. Yen, and G. Lee, "Disease-related modifications in tau affect the interaction between Fyn and tau, " Journal of Biological Chemistry, vol. 280, no. 42, pp. 35119-35125, 2005.
89. C. H. Reynolds, C. J. Garwood, S. Wray et al., "Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cγ1, Grb2, and Src family kinases, "The Journal of Biological Chemistry, vol. 283, no. 26, pp. 18177-18186, 2008.
90. R. Brandt, M. Hundelt, andN. Shahani, "Taualterationandneuronal degeneration in tauopathies: mechanisms and models, " Biochimica et Biophysica Acta, vol. 1739, no. 2-3, pp. 331-354, 2005.
91. M. Goedert, R. Jakes, and R. A. Crowther, "Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments, " FEBS Letters, vol. 450, no. 3, pp. 306-311, 1999.
92. M. Deture, L. Ko, S. Yen et al., "Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions, " Brain Research, vol. 853, no. 1, pp. 5-14, 2000.
93. P. Nacharaju, J. Lewis, C. Easson et al., "Accelerated filament formation from tau protein with specific FTDP-17 missense mutations, " FEBS Letters, vol. 447, no. 2-3, pp. 195-199, 1999.
94. M. Goedert and M. G. Spillantini, "Taumutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimers disease, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1502, no. 1, pp. 110-121, 2000.
95. G. Mairet-Coello, J. Courchet, S. Pieraut, V. Courchet, A. Maximov, and F. Polleux, "The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation, " Neuron, vol. 78, no. 1, pp. 94-108, 2013.
96. M. Jin, N. Shepardson, T. Yang, G. Chen, D. Walsh, and D. J. Selkoe, "Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration, " Proceedings of theNationalAcademy of Sciences of the United States of America, vol. 108, no. 14, pp. 5819-5824, 2011.
97. H. Zempel, E. Thies, and E. Mandelkow, "Aβ oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines, " The Journal of Neuroscience, vol. 30, no. 36, pp. 11938-11950, 2010.
98. M. Rapoport, H. N. Dawson, L. I. Binder, M. P. Vitek, and A. Ferreira, "Tau is essential to β-amyloid-induced neurotoxicity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 9, pp. 6364-6369, 2002.
99. D. P. Hanger, B. H. Anderton, andW. Noble, "Tau phosphorylation: the therapeutic challenge for neurodegenerative disease, " Trends in Molecular Medicine, vol. 15, no. 3, pp. 112-119, 2009.
100. G. Lee and C. J. Leugers, "Tau and tauopathies, " Progress in Molecular Biology and Translational Science, vol. 107, pp. 263-293, 2012.
101. J. Biernat, N. Gustke, G. Drewes, and E. Mandelkow, "Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding, " Neuron, vol. 11, no. 1, pp. 153-163, 1993.
102. X. Li, Y. Kumar, H. Zempel, E. Mandelkow, J. Biernat, and E. Mandelkow, "Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration, " EMBO Journal, vol. 30, no. 23, pp. 4825-4837, 2011.
103. K. Iijima, A. Gatt, and K. Iijima-Ando, "Tau Ser262 phosphorylation is critical for Aβ42-induced tau toxicity in a transgenic Drosophila model of Alzheimers disease, " Human Molecular Genetics, vol. 19, no. 15, pp. 2947-2957, 2010.
104. W. Yu, J. Polepalli, D. Wagh, J. Rajadas, R. Malenka, and B. Lu, "A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines, " Human Molecular Genetics, vol. 21, no. 6, pp. 1384-1390, 2012.
105. J. Bertrand, V. Plouffe, P. Senechal, and N. Leclerc, "The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons, " Neuroscience, vol. 168, no. 2, pp. 323-334, 2010.
106. J. L. Twiss, J. H. Chang, andN. C. Schanen, "Pathophysiological mechanisms for actions of the neurotrophins, " Brain Pathology, vol. 16, no. 4, pp. 320-332, 2006.
107. M. Bibel and Y. Barde, "Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system, " Genes and Development, vol. 14, no. 23, pp. 2919-2937, 2000.
108. A. J. Kole, R. P. Annis, and M. Deshmukh, "Mature neurons: equipped for survival, " Cell Death & Disease, vol. 4, article e689, 2013.
109. L. Colucci-DAmato, C. Perrone-Capano, and U. di Porzio, "Chronic activation of ERK and neurodegenerative diseases, " BioEssays, vol. 25, no. 11, pp. 1085-1095, 2003.
110. X. Zhu, H. Lee, A. K. Raina, G. Perry, andM. A. Smith, "Therole of mitogen-activated protein kinase pathways in Alzheimer's disease, " NeuroSignals, vol. 11, no. 5, pp. 270-281, 2002.
111. G. M. Thomas and R. L. Huganir, "MAPK cascade signalling and synaptic plasticity, " Nature Reviews Neuroscience, vol. 5, no. 3, pp. 173-183, 2004.
112. S. S. Grewal, R. D. York, and P. J. Stork, "Extracellular-signalregulated kinase signalling in neurons, " Current Opinion in Neurobiology, vol. 9, no. 5, pp. 544-553, 1999.
113. I. Wortzel and R. Seger, "The ERK cascade: distinct functions within various subcellular organelles, " Genes and Cancer, vol. 2, no. 3, pp. 195-209, 2011.
114. C. J. Marshall, "Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation, " Cell, vol. 80, no. 2, pp. 179-185, 1995.
115. C. J. Caunt and S. M. Keyse, "Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling, " FEBS Journal, vol. 280, no. 2, pp. 489-504, 2013.
116. M. Stanciu and D. B. Defranco, "Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line, " Journal of Biological Chemistry, vol. 277, no. 6, pp. 4010-4017, 2002.
117. S. Subramaniam, J. Strelau, and K. Unsicker, "Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways, "The Journal of Biological Chemistry, vol. 278, no. 11, pp. 8904-8912, 2003.
118. S. M. Kulich and C. T. Chu, "Sustained extracellular signalregulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease, " Journal of Neurochemistry, vol. 77, no. 4, pp. 1058-1066, 2001.
119. M. Stanciu, Y. Wang, R. Kentor et al., "Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures, " The Journal of Biological Chemistry, vol. 275, no. 16, pp. 12200-12206, 2000.
120. Q. Jiang, Z. Gu, and G. Zhang, "Nuclear translocation of extracellular signal-regulated kinases in neuronal excitotoxicity, " NeuroReport, vol. 12, no. 11, pp. 2417-2421, 2001.
121. M. Gralle and S. T. Ferreira, "Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts, " Progress in Neurobiology, vol. 82, no. 1, pp. 11-32, 2007.
122. E. A. Milward, R. Papadopoulos, S. J. Fuller et al., "The amyloid protein precursor of Alzheimers disease is a mediator of the effects of nerve growth factor on neurite outgrowth, " Neuron, vol. 9, no. 1, pp. 129-137, 1992.
123. K. Jin, V. Galvan, L. Xie et al., "Enhanced neurogenesis in Alzheimers disease transgenic (PDGF-APP Sw, Ind) mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13363-13367, 2004.
124. Y. Yu, J. He, Y. Zhang et al., "Increased hippocampal neurogenesis in the progressive stage of Alzheimers disease phenotype in an APP/PS1 double transgenic mouse model, " Hippocampus, vol. 19, no. 12, pp. 1247-1253, 2009.
125. P. Porayette, M. J. Gallego, M. M. Kaltcheva, R. L. Bowen, S. V. Meethal, and C. S. Atwood, "Differential processing of amyloid-β precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells, " The Journal of Biological Chemistry, vol. 284, no. 35, pp. 23806-23817, 2009.
126. M. A. Lopez-Toledano and M. L. Shelanski, "Neurogenic effect of β-amyloid peptide in the development of neural stem cells, " TheJournal ofNeuroscience, vol. 24, no. 23, pp. 5439-5444, 2004.
127. C. Heo, K. Chang, H. S. Choi et al., "Effects of the monomeric, oligomeric, and fibrillar Aβ42 peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone, " Journal of Neurochemistry, vol. 102, no. 2, pp. 493-500, 2007.
128. M. Calafiore, G. Battaglia, A. Zappala et al., "Progenitor cells from the adult mouse brain acquire a neuronal phenotype in response to β-amyloid, " Neurobiology of Aging, vol. 27, no. 4, pp. 606-613, 2006.
129. B. A. Yankner, L. K. Duffy, and D. A. Kirschner, "Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides, " Science, vol. 250, no. 4978, pp. 279-282, 1990.
130. M. P. Mazanetz and P. M. Fischer, "Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases, " Nature Reviews Drug Discovery, vol. 6, no. 6, pp. 464-479, 2007.
131. Y. Zheng, B. Li, J. Kanungo et al., "Cdk5modulation ofmitogenactivated protein kinase signaling regulates neuronal survival, " Molecular Biology of the Cell, vol. 18, no. 2, pp. 404-413, 2007.
132. R. E. Tanzi, "The genetics of Alzheimer disease, " Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 10, 2012.
133. M. S. Wolfe, "When loss is gain: reduced presenilin proteolytic function leads to increased Aβ42/Aβ40. Talking Point on the role of presenilin mutations in Alzheimer disease, " EMBO Reports, vol. 8, no. 2, pp. 136-140, 2007.
134. M. H. Park, D. Y. Choi, H. W. Jin et al., "Mutant presenilin 2 increases β-secretase activity through reactive oxygen speciesdependent activation of extracellular signal-regulated kinase, " Journal of Neuropathology & Experimental Neurology, vol. 71, no. 2, pp. 130-139, 2012.
135. D. E. Kang, I. S. Yoon, E. Repetto et al., "Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors: selectivity of PS2 in platelet-derived growth factor signaling, " The Journal of Biological Chemistry, vol. 280, no. 36, pp. 31537-31547, 2005.
136. K. M. Korwek, J. H. Trotter, M. J. Ladu, P. M. Sullivan, and E. J. Weeber, "Apoe isoform-dependent changes in hippocampal synaptic function, " Molecular Neurodegeneration, vol. 4, no. 1, article 21, 2009.
137. G. Bu, "Apolipoprotein e and its receptors in Alzheimers disease: athways, pathogenesis and therapy, " Nature Reviews Neuroscience, vol. 10, no. 5, pp. 333-344, 2009.
138. A. Lleo, E. Waldron, C. A. F. Von Arnim et al., "Low density lipoprotein receptor-related protein (LRP) interacts with presenilin and is a competitive substrate of the amyloid precursor protein (APP) for γ-secretase, "The Journal of Biological Chemistry, vol. 280, no. 29, pp. 27303-27309, 2005.
139. R. B. DeMattos, J. R. Cirrito, M. Parsadanian et al., "ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abetametabolism in vivo, " Neuron, vol. 41, no. 2, pp. 193-202, 2004.
140. F. M. Harris, W. J. Brecht, Q. Xu, R. W. Mahley, and Y. Huang, "Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc, " The Journal of Biological Chemistry, vol. 279, no. 43, pp. 44795-44801, 2004.
141. T. E. Willnow, A. Carlo, M. Rohe, and V. Schmidt, "SORLA/SORL1, a neuronal sorting receptor implicated in Alzheimers disease, " Reviews in the Neurosciences, vol. 21, no. 4, pp. 315-329, 2010.
142. S. Glerup, M. Lume, D. Olsen et al., "SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFRα1 and RET, " Cell Reports, vol. 3, no. 1, pp. 186-199, 2013.
143. D. Nie, A. di Nardo, J. M. Han et al., "Tsc2-Rheb signaling regulates EphA-mediated axon guidance, " Nature Neuroscience, vol. 13, no. 2, pp. 163-172, 2010.
144. S. Elowe, S. J. Holland, S. Kulkarni, and T. Pawson, "Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrininduced neurite retraction, "Molecular and Cellular Biology, vol. 21, no. 21, pp. 7429-7441, 2001.
145. T. B. Huber, B. Hartleben, J. Kim et al., "Nephrin and CD2AP associate with phosphoinositide 3-OH kinase and stimulate AKT-dependent signaling, "Molecular and Cellular Biology, vol. 23, no. 14, pp. 4917-4928, 2003.
146. R. Killick, E. M. Ribe, R. Al-Shawi et al., "Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway, " Molecular Psychiatry, vol. 19, no. 1, pp. 88-98, 2012.
147. S. Y. Gil, B. Youn, K. Byun et al., "Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway, " Nature Communications, vol. 4, article 1862, 2013.
148. P. Narayan, A. Orte, R. W. Clarke et al., "The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β 1-40 peptide, " Nature Structural and Molecular Biology, vol. 19, no. 1, pp. 79-83, 2012.
149. D. Wang, Q. Fu, Y. Zhou et al., "β2 adrenergic receptor, protein kinase a (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in alzheimer disease models, " The Journal of Biological Chemistry, vol. 288, no. 15, pp. 10298-10307, 2013.
150. J. T. Yu, L. Tan, J. Ou et al., "Polymorphisms at the β2-adrenergic receptor gene influence Alzheimer's disease susceptibility, " Brain Research, vol. 1210, pp. 216-222, 2008.
151. A. Griciuc, A. Serrano-Pozo, A. R. Parrado et al., "Alzheimers disease risk gene cd33 inhibits microglial uptake of amyloid beta, " Neuron, vol. 78, no. 4, pp. 631-643, 2013.
152. Q. Xiao, S. Gil, P. Yan et al., "Role of Phosphatidylinositol Clathrin Assembly Lymphoid-Myeloid Leukemia (PICALM) in intracellular Amyloid Precursor Protein (APP) processing and amyloid plaque pathogenesis, " Journal of Biological Chemistry, vol. 287, no. 25, pp. 21279-21289, 2012.
153. M. S. Tan, J. T. Yu, and L. Tan, "Bridging integrator 1 (BIN1): form, function, and Alzheimers disease, " Trends in Molecular Medicine, vol. 19, no. 10, pp. 594-603, 2013.
154. W. S. Kim, H. Li, K. Ruberu et al., "Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimers disease, " Journal of Neuroscience, vol. 33, no. 10, pp. 4387-4394, 2013.
155. C. T. Chu, D. J. Levinthal, S. M. Kulich, E. M. Chalovich, and D. B. DeFranco, "Oxidative neuronal injury: the dark side of ERK1/2, " European Journal of Biochemistry, vol. 271, no. 11, pp. 2060-2066, 2004.
156. Y.-S. Ho, X. Yang, S.-C. Yeung et al., "Cigarette smoking accelerated brain aging and induced pre-alzheimer-like neuropathology in rats, " PLoS ONE, vol. 7, no. 5, Article ID e36752, 2012.
157. S. J. Greco, S. Sarkar, J. M. Johnston, and N. Tezapsidis, "Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells, " Biochemical and Biophysical Research Communications, vol. 380, no. 1, pp. 98-104, 2009.
158. S. Mehan, H. Meena, D. Sharma, and R. Sankhla, "JNK: a stressactivated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities, " Journal of Molecular Neuroscience, vol. 43, no. 3, pp. 376-390, 2011.
159. S. A. Correa and K. L. Eales, "Therole of p38MAPK and its substrates in neuronal plasticity and neurodegenerative disease, " Journal of Signal Transduction, vol. 2012, Article ID 649079, 12 pages, 2012.
160. R. A. Quintanilla, D. I. Orellana, C. Gonzalez-Billault, and R. B. Maccioni, "Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway, " Experimental Cell Research, vol. 295, no. 1, pp. 245-257, 2004.
161. J. T. Neary, "Protein kinase signaling cascades in CNS trauma, " IUBMB Life, vol. 57, no. 11, pp. 711-718, 2005.
162. H. B. Schioth, S. Craft, S. J. Brooks, W. H. Frey II, and C. Benedict, "Brain insulin signaling and Alzheimers disease: current evidence and future directions, " Molecular Neurobiology, vol. 46, no. 1, pp. 4-10, 2012.
163. I. Sotiropoulos, C. Catania, L. G. Pinto et al., "Stress acts cumulatively to precipitateAlzheimers disease-like tau pathology and cognitive deficits, " Journal of Neuroscience, vol. 31, no. 21, pp. 7840-7847, 2011.
164. R. A. Rissman, K. Lee, W. Vale, and P. E. Sawchenko, "Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation, " Journal of Neuroscience, vol. 27, no. 24, pp. 6552-6562, 2007.
165. M. Xia and B. T. Hyman, "GROα/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation: a role in Alzheimers disease?" Journal of Neuroimmunology, vol. 122, no. 1-2, pp. 55-64, 2002.
166. R. Quiroz-Baez, E. Rojas, and C. Arias, "Oxidative stress promotes JNK-dependent amyloidogenic processing of normally expressed human APP by differential modification of α-, β-and γ-secretase expression, " Neurochemistry International, vol. 55, no. 7, pp. 662-670, 2009.
167. H. Le Freche, J. Brouillette, F. Fernandez-Gomez et al., "Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment, " Anesthesiology, vol. 116, no. 4, pp. 779-787, 2012.
168. R. A. Whittington, L. Virag, F. Marcouiller et al., "Propofol directly increases tau phosphorylation, " PLoS ONE, vol. 6, no. 1, Article ID e16648, 2011.
169. M. A. Papon, R. A. Whittington, N. B. El-Khoury, andE. Planel, "Alzheimers disease and anesthesia, " Frontiers in Neuroscience, vol. 4, article 272, 2011.
170. X. Run, Z. Liang, L. Zhang, K. Iqbal, I. Grundke-Iqbal, and C. Gong, "Anesthesia induces phosphorylation of tau, " Journal of Alzheimers Disease, vol. 16, no. 3, pp. 619-626, 2009.
171. B. Giunta, F. Fernandez, W. V. Nikolic et al., "Inflammaging as a prodrome to Alzheimers disease, " Journal of Neuroinflammation, vol. 5, article 51, 2008.
172. E. C. Toescu and A. Verkhratsky, "The importance of being subtle: Small changes in calcium homeostasis control cognitive decline in normal aging, " Aging Cell, vol. 6, no. 3, pp. 267-273, 2007.
173. M. Goto, "Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory?" BioScience Trends, vol. 2, no. 6, pp. 218-230, 2008.
174. F. Yin, H. Sancheti, and E. Cadenas, "Mitochondrial thiols in the regulation of cell death pathways, " Antioxidants and Redox Signaling, vol. 17, no. 12, pp. 1714-1727, 2012.
175. M. Sakono and T. Zako, "Amyloid oligomers: formation and toxicity ofAβ oligomers, " FEBS Journal, vol. 277, no. 6, pp. 1348-1358, 2010.
176. W.-Q. Zhao, F. G. de Felice, S. Fernandez et al., "Amyloid beta oligomers induce impairment of neuronal insulin receptors, " The FASEB Journal, vol. 22, no. 1, pp. 246-260, 2008.
177. W. Fu, A. Ruangkittisakul, D. MacTavish, J. Y. Shi, K. Ballanyi, and J. H. Jhamandas, "Amyloid β (Aβ) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways, " The Journal of Biological Chemistry, vol. 287, no. 22, pp. 18820-18830, 2012.
178. I. L. Ferreira, L. M. Bajouco, S. I. Mota, Y. P. Auberson, C. R. Oliveira, and A. C. Rego, "Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures, " Cell Calcium, vol. 51, no. 2, pp. 95-106, 2012.
179. L. Texido, M. Martin-Satue, E. Alberdi, C. Solsona, and C. Matute, "Amyloid β peptide oligomers directly activate NMDA receptors, " Cell Calcium, vol. 49, no. 3, pp. 184-190, 2011.
180. S. Li, M. Jin, T. Koeglsperger, N. E. Shepardson, G. M. Shankar, and D. J. Selkoe, "Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors, " Journal of Neuroscience, vol. 31, no. 18, pp. 6627-6638, 2011.
181. H. Decker, S. Jurgensen, M. F. Adrover et al., "N-Methyld-aspartate receptors are required for synaptic targeting of Alzheimers toxic amyloid-β peptide oligomers, " Journal of Neurochemistry, vol. 115, no. 6, pp. 1520-1529, 2010.
182. R. Malinow, "New developments on the role of NMDA receptors in Alzheimers disease, " Current Opinion in Neurobiology, vol. 22, no. 3, pp. 559-563, 2012.
183. K. T. Dineley, M. Westerman, D. Bui, K. Bell, K. H. Ashe, and J. D. Sweatt, " β-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In Vitro and in Vivo mechanisms related to Alzheimers disease, " Journal of Neuroscience, vol. 21, no. 12, pp. 4125-4133, 2001.
184. S. D. Buckingham, A. K. Jones, L. A. Brown, and D. B. Sattelle, "Nicotinic acetylcholine receptor signalling: roles in alzheimers disease and amyloid neuroprotection, " Pharmacological Reviews, vol. 61, no. 1, pp. 39-61, 2009.
185. N. C. Inestrosa and E. M. Toledo, "The role of Wnt signaling in neuronal dysfunction in Alzheimers Disease, " Molecular Neurodegeneration, vol. 3, no. 1, article 9, 2008.
186. M. H. Magdesian, M. M. V. F. Carvalho, F. A. Mendes et al., "Amyloid-β binds to the extracellular cysteine-rich domain of frizzled and inhibits Wnt/β-catenin signaling, " Journal of Biological Chemistry, vol. 283, no. 14, pp. 9359-9368, 2008.
187. C. ONeill, A. P. Kiely, M. F. Coakley, S. Manning, and C. M. Long-Smith, "Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimers disease, " Biochemical Society Transactions, vol. 40, no. 4, pp. 721-727, 2012.
188. N. Origlia, M. Righi, S. Capsoni et al., "Receptor for advanced glycation end product-dependent activation of p38 mitogenactivated protein kinase contributes to amyloid-β-mediated cortical synaptic dysfunction, " The Journal of Neuroscience, vol. 28, no. 13, pp. 3521-3530, 2008.
189. B. A. Yankner, A. Caceres, and L. K. Duffy, "Nerve growth factor potentiates the neurotoxicity of β amyloid, " Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 22, pp. 9020-9023, 1990.
190. J. T. Yu, N. Wang, T. Ma, H. Jiang, J. Guan, and L. Tan, "Roles of β-adrenergic receptors in Alzheimer's disease: implications for novel therapeutics, " Brain Research Bulletin, vol. 84, no. 2, pp. 111-117, 2011.
191. D. Wang, G. Govindaiah, R. Liu, V. de Arcangelis, C. L. Cox, and Y. K. Xiang, "Binding of amyloid β peptide to β2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity, " FASEB Journal, vol. 24, no. 9, pp. 3511-3521, 2010.
192. E. Mandelkow, "Biochemistry and cell biology of tau protein in neurofibrillary degeneration, " Cold Spring Harbor perspectives in medicine, vol. 2, no. 7, Article ID a006247, 2012.
193. S. Kar, J. Fan, M. J. Smith, M. Goedert, and L. A. Amos, "Repeat motifs of tau bind to the insides of microtubules in the absence of taxol, " EMBO Journal, vol. 22, no. 1, pp. 70-77, 2003.
194. T. A. Fulga, I. Elson-Schwab, V. Khurana et al., "Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo, " Nature Cell Biology, vol. 9, no. 2, pp. 139-148, 2007.
195. W. J. Strittmatter, A. M. Saunders, M. Goedert et al., "Isoformspecific interactions of apolipoprotein E with microtubuleassociated protein tau: implications for Alzheimer disease, " Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 11183-11186, 1994.
196. L. M. Fleming, K. H. Weisgraber, W. J. Strittmatter, J. C. Troncoso, and G. V. W. Johnson, "Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins, " Experimental Neurology, vol. 138, no. 2, pp. 252-260, 1996.
197. Z. Jing, J. Caltagarone, and R. Bowser, "Altered subcellular distribution of c-Abl in alzheimers disease, " Journal of Alzheimers Disease, vol. 17, no. 2, pp. 409-422, 2009.
198. S. M. Jenkins and G. V. W. Johnson, "Tau complexes with phospholipase C-γ in situ, " NeuroReport, vol. 9, no. 1, pp. 67-71, 1998.
199. W. Sun, H. Y. Qureshi, P. W. Cafferty et al., "Glycogen synthase kinase-3′ is complexed with tau protein in brain microtubules, " Journal of Biological Chemistry, vol. 277, no. 14, pp. 11933-11940, 2002.
200. R. Padilla, R. B. Maccioni, and J. Avila, "Calmodulin binds to a tubulin binding site of the microtubule-associated protein tau, " Molecular and Cellular Biochemistry, vol. 97, no. 1, pp. 35-41, 1990.
201. Y. C. Lee and J. Wolff, "Calmodulin binds to both microtubuleassociated protein 2 and τ proteins, " Journal of Biological Chemistry, vol. 259, no. 2, pp. 1226-1230, 1984.
202. N. N. Sluchanko, A. S. Seit-Nebi, andN. B. Gusev, "Phosphorylation of more than one site is required for tight interaction of human tau protein with 14-3-3zeta, " FEBS Letters, vol. 583, no. 17, pp. 2739-2742, 2009.
203. N. N. Sluchanko, A. S. Seit-Nebi, and N. B. Gusev, "Effect of phosphorylation on interaction of human tau protein with 14-3-3ζ, " Biochemical and Biophysical Research Communications, vol. 379, no. 4, pp. 990-994, 2009.
204. M. Hashiguchi, K. Sobue, and H. K. Paudel, "14-3-3ζ is an effector of tau protein phosphorylation, " Journal of Biological Chemistry, vol. 275, no. 33, pp. 25247-25254, 2000.
205. A. Gauthier-Kemper, C. Weissmann, N. Golovyashkina et al., "The frontotemporal dementia mutation R406W blocks taus interaction with the membrane in an annexin A2-dependent manner, "The Journal of Cell Biology, vol. 192, no. 4, pp. 647-661, 2011.
206. C. Smet, A. Sambo, J. Wieruszeski et al., "The peptidyl prolyl cis/trans-isomerase Pin1 recognizes the phospho-Thr212-Pro213 site on Tau, " Biochemistry, vol. 43, no. 7, pp. 2032-2040, 2004.
207. P.-J. Lu, G. Wulf, X. Z. Zhou, P. Davies, and K. P. Lu, "The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein, " Nature, vol. 399, no. 6738, pp. 784-788, 1999.